Skip to main content

Flora Growth Withdraws Planned Public Share Offering Amid ZeroStack Rebrand

Tipranks - Thu Jan 29, 8:32AM CST

Claim 50% Off TipRanks Premium

Flora Growth ( (FLGC) ) has shared an update.

Flora Growth Corp., which plans to operate under the ZeroStack name, has withdrawn its proposed public offering of common shares, halting a planned capital-raising move in the public markets. The decision removes a near-term equity issuance overhang and may signal a reassessment of market conditions or financing strategy as the company refocuses its positioning around decentralized AI asset management and continues to leverage its pharmaceutical distribution business through Phatebo GmbH.

The most recent analyst rating on (FLGC) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Flora Growth stock, see the FLGC Stock Forecast page.

Spark’s Take on FLGC Stock

According to Spark, TipRanks’ AI Analyst, FLGC is a Neutral.

The score is held down primarily by weak financial performance (declining revenue, ongoing losses, and negative operating/free cash flow). Technicals are mixed (short-term strength but longer-term downtrend and overbought RSI), while corporate events modestly support the outlook through financing flexibility and improved governance; valuation remains constrained due to negative earnings and no indicated dividend yield.

To see Spark’s full report on FLGC stock, click here.

More about Flora Growth

Flora Growth Corp., soon to be rebranded as ZeroStack, is a Nasdaq-listed asset management company focused on providing investor exposure to decentralized artificial intelligence. The company also runs a global pharmaceutical distribution operation through its wholly owned subsidiary, Phatebo GmbH, giving it a dual presence in both emerging AI-focused financial products and international pharma markets.

Average Trading Volume: 64,918

Technical Sentiment Signal: Sell

Current Market Cap: $6.61M

Find detailed analytics on FLGC stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.